drugset / Trial / NCT04467723
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Phase 1/2
Recruiting
25 enrolled
University of Kansas Medical Center
parkview cancer institute · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
Timeline
- Start
- 2022-05-18
- Primary completion
- 2027-01-01
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Pirfenidone | Small molecule | 801 mg | Oral |